

# World Journal of *Clinical Cases*

*World J Clin Cases* 2019 December 6; 7(23): 3915-4171



**REVIEW**

- 3915** Overview of organic anion transporters and organic anion transporter polypeptides and their roles in the liver  
*Li TT, An JX, Xu JY, Tuo BG*

**ORIGINAL ARTICLE****Observational Study**

- 3934** Value of early diagnosis of sepsis complicated with acute kidney injury by renal contrast-enhanced ultrasound  
*Wang XY, Pang YP, Jiang T, Wang S, Li JT, Shi BM, Yu C*
- 3945** Value of elastography point quantification in improving the diagnostic accuracy of early diabetic kidney disease  
*Liu QY, Duan Q, Fu XH, Fu LQ, Xia HW, Wan YL*
- 3957** Resection of recurrent third branchial cleft fistulas assisted by flexible pharyngotomy  
*Ding XQ, Zhu X, Li L, Feng X, Huang ZC*
- 3964** Therapeutic efficacy of acupuncture combined with neuromuscular joint facilitation in treatment of hemiplegic shoulder pain  
*Wei YH, Du DC, Jiang K*
- 3971** Comparison of intra-articular injection of parecoxib *vs* oral administration of celecoxib for the clinical efficacy in the treatment of early knee osteoarthritis  
*Lu L, Xie Y, Gan K, Huang XW*

**Retrospective Study**

- 3980** Celiomesenteric trunk: New classification based on multidetector computed tomography angiographic findings and probable embryological mechanisms  
*Tang W, Shi J, Kuang LQ, Tang SY, Wang Y*

**Prospective Study**

- 3990** Interaction of arylsulfatases A and B with maspin: A possible explanation for dysregulation of tumor cell metabolism and invasive potential of colorectal cancer  
*Kovacs Z, Jung I, Szalman K, Baniás L, Bara TJ, Gurzu S*

**CASE REPORT**

- 4004** Recuperation of severe tumoral calcinosis in a dialysis patient: A case report  
*Westermann L, Isbell LK, Breitenfeldt MK, Arnold F, Röthele E, Schneider J, Widmeier E*

- 4011** Robotic wedge resection of a rare gastric perivascular epithelioid cell tumor: A case report  
*Marano A, Maione F, Woo Y, Pellegrino L, Geretto P, Sasia D, Fortunato M, Orcioni GF, Priotto R, Fasoli R, Borghi F*
- 4020** Primary parahiatal hernias: A case report and review of the literature  
*Preda SD, Pătrașcu Ș, Ungureanu BS, Cristian D, Bințișan V, Nica CM, Calu V, Strâmbu V, Sapalidis K, Șurlin VM*
- 4029** Diagnosis of Laron syndrome using monoplex-polymerase chain reaction technology with a whole-genome amplification template: A case report  
*Neumann A, Alcántara-Ortigoza MÁ, González-del Ángel A, Camargo-Diaz F, López-Bayghen E*
- 4036** *In-vitro* proliferation assay with recycled ascitic cancer cells in malignant pleural mesothelioma: A case report  
*Anayama T, Taguchi M, Tatenuma T, Okada H, Miyazaki R, Hirohashi K, Kume M, Matsusaki K, Orihashi K*
- 4044** Distant metastasis in choroidal melanoma with spontaneous corneal perforation and intratumoral calcification: A case report  
*Wang TW, Liu HW, Bee YS*
- 4052** Secondary Parkinson disease caused by breast cancer during pregnancy: A case report  
*Li L*
- 4057** Pulmonary embolism and deep vein thrombosis caused by nitrous oxide abuse: A case report  
*Sun W, Liao JP, Hu Y, Zhang W, Ma J, Wang GF*
- 4063** Micronodular thymic tumor with lymphoid stroma: A case report and review of the literature  
*Wang B, Li K, Song QK, Wang XH, Yang L, Zhang HL, Zhong DR*
- 4075** Diffuse large B cell lymphoma with bilateral adrenal and hypothalamic involvement: A case report and literature review  
*An P, Chen K, Yang GQ, Dou JT, Chen YL, Jin XY, Wang XL, Mu YM, Wang QS*
- 4084** Urethral pressure profilometry in artificial urinary sphincter implantation: A case report  
*Meng LF, Liu XD, Wang M, Zhang W, Zhang YG*
- 4091** Hydroxyurea-induced cutaneous squamous cell carcinoma: A case report  
*Xu Y, Liu J*
- 4098** Recurrent hypotension induced by sacubitril/valsartan in cardiomyopathy secondary to Duchenne muscular dystrophy: A case report  
*Li JM, Chen H*
- 4106** Complete duodenal obstruction induced by groove pancreatitis: A case report  
*Wang YL, Tong CH, Yu JH, Chen ZL, Fu H, Yang JH, Zhu X, Lu BC*

- 4111** Radiological aspects of giant hepatocellular adenoma of the left liver: A case report  
*Zheng LP, Hu CD, Wang J, Chen XJ, Shen YY*
- 4119** Mixed serous-neuroendocrine neoplasm of the pancreas: A case report and review of the literature  
*Xu YM, Li ZW, Wu HY, Fan XS, Sun Q*
- 4130** Rigid esophagoscopy combined with angle endoscopy for treatment of superior mediastinal foreign bodies penetrating into the esophagus caused by neck trauma: A case report  
*Wang D, Gao CB*
- 4137** Left armpit subcutaneous metastasis of gastric cancer: A case report  
*He FJ, Zhang P, Wang MJ, Chen Y, Zhuang W*
- 4144** Bouveret syndrome: A case report  
*Wang F, Du ZQ, Chen YL, Chen TM, Wang Y, Zhou XR*
- 4150** Fatal complications in a patient with severe multi-space infections in the oral and maxillofacial head and neck regions: A case report  
*Dai TG, Ran HB, Qiu YX, Xu B, Cheng JQ, Liu YK*
- 4157** Management of massive fistula bleeding after endoscopic ultrasound-guided pancreatic pseudocyst drainage using hemostatic forceps: A case report  
*Ge N, Sun SY*
- 4163** Pure squamous cell carcinoma of the gallbladder locally invading the liver and abdominal cavity: A case report and review of the literature  
*Jin S, Zhang L, Wei YF, Zhang HJ, Wang CY, Zou H, Hu JM, Jiang JF, Pang LJ*

**ABOUT COVER**

Editorial Board Member of *World Journal of Clinical Cases*, Consolato M Sergi, FRCP (C), MD, PhD, Professor, Department of Lab Medicine and Pathology, University of Alberta, Edmonton T6G 2B7, Canada

**AIMS AND SCOPE**

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

**INDEXING/ABSTRACTING**

The WJCC is now indexed in PubMed, PubMed Central, Science Citation Index Expanded (also known as SciSearch®), and Journal Citation Reports/Science Edition. The 2019 Edition of Journal Citation Reports cites the 2018 impact factor for WJCC as 1.153 (5-year impact factor: N/A), ranking WJCC as 99 among 160 journals in Medicine, General and Internal (quartile in category Q3).

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Responsible Electronic Editor: *Yan-Xia Xing*

Proofing Production Department Director: *Xiang Li*

**NAME OF JOURNAL**

*World Journal of Clinical Cases*

**ISSN**

ISSN 2307-8960 (online)

**LAUNCH DATE**

April 16, 2013

**FREQUENCY**

Semimonthly

**EDITORS-IN-CHIEF**

Dennis A Bloomfield, Bao-Gan Peng, Sandro Vento

**EDITORIAL BOARD MEMBERS**

<https://www.wjnet.com/2307-8960/editorialboard.htm>

**EDITORIAL OFFICE**

Jin-Lei Wang, Director

**PUBLICATION DATE**

December 6, 2019

**COPYRIGHT**

© 2019 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjnet.com/bpg/gerinfo/240>

**PUBLICATION MISCONDUCT**

<https://www.wjnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>

## Diagnosis of Laron syndrome using monoplex-polymerase chain reaction technology with a whole-genome amplification template: A case report

Adina Neumann, Miguel Ángel Alcántara-Ortigoza, Ariadna González-del Ángel, Felipe Camargo-Díaz, Esther López-Bayghen

**ORCID number:** Adina Neumann (0000-0002-2563-8540); Miguel Ángel Alcántara-Ortigoza (0000-0003-0592-8214); Ariadna González-del Ángel (0000-0002-7096-0969); Felipe Camargo-Díaz (0000-0001-8256-5264); Esther López-Bayghen (0000-0002-2849-7587).

**Author contributions:** All authors contributed to this work.

**Supported by** Conacyt, NO. 231793.

**Informed consent statement:** The intervention protocol has approved by the Ethics Committee of the Ingenes Institute (approval number ISF300316). Both patients provided written informed consent to participate in this study, in accordance with the Declaration of Helsinki. Written informed consent was obtained from the patient(s) for their anonymized information to be published in this article.

**Conflict-of-interest statement:** The authors declare no conflict of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article which was selected by an in-house editor and

**Adina Neumann, Felipe Camargo-Díaz,** Laboratorio de Investigación y Diagnóstico Molecular, Instituto de Infertilidad y Genética México SC, INGENES, México City 05320, México

**Miguel Ángel Alcántara-Ortigoza, Ariadna González-del Ángel,** Instituto Nacional de Pediatría, Torre de Investigación, Mexico City 04530, México

**Miguel Ángel Alcántara-Ortigoza, Ariadna González-del Ángel,** Laboratorio de Biología Molecular, Departamento de Genética Humana, Instituto Nacional de Pediatría, México City 04530, México

**Esther López-Bayghen,** Departamento de Toxicología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), México City 07360, México

**Corresponding author:** Esther López-Bayghen, MSc, PhD, Academic Research, Professor, Senior Researcher, Senior Scientist, Departamento de Toxicología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Avenida Instituto Politécnico Nacional 2508, San Pedro Zacatenco, México City 07360, México.

[ebayghen@cinvestav.mx](mailto:ebayghen@cinvestav.mx)

**Telephone:** +52-55-57473800

### Abstract

#### BACKGROUND

Laron syndrome (LS) is an autosomal recessive hereditary condition affecting only 1/1000000 births. The cause is associated with mutations in the growth hormone (GH) receptor (GHR), leading to GH insensitivity. LS patients typically present with severe growth retardation, obesity, and abnormal sexual maturation. Currently, LS diagnosis is performed post-delivery. Therefore, we assessed the efficiency of Pre-implantation Genetic Testing (PGT) coupled with monoplex-polymerase chain reaction (PCR) technology for detecting this monogenic disease in embryos from a couple confirmed as LS heterozygous carriers

#### CASE SUMMARY

The couple LS-carriers were confirmed by the presence of a first child born with LS. The couple underwent a standard *in vitro* fertilization (IVF) protocol. DNA was collected from trophectoderm cells from day 5 embryos. Whole genome amplification (WGA) was performed using a Sureplex DNA Amplification



fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

<http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Received:** September 8, 2019

**Peer-review started:** September 8, 2019

**First decision:** October 24, 2019

**Revised:** October 31, 2019

**Accepted:** November 14, 2019

**Article in press:** November 14, 2019

**Published online:** December 6, 2019

**P-Reviewer:** Settin A

**S-Editor:** Yan JP

**L-Editor:** A

**E-Editor:** Wu YXJ



System and analyzed by PCR, targeting the deletion of the exons 5 and 6 in the *GHR* gene as well as PGT by Next-generation Sequencing (Illumina). Eleven embryos were collected and analyzed. 27.3% were the wild type for GHR, 45.5% were heterozygotes, and 18.2% homozygous mutants. One embryo yielded no results. Three 2-embryos transfers were performed; 2 normal homozygous and four heterozygous carriers were selected for transfer. The first two transfers were unsuccessful, whereas the final transfer with two heterozygous embryos resulted in clinical pregnancy. The genomic composition of the fetus was verified, applying the same techniques using amniocytes, extracted after 21 wk of the ongoing pregnancy. The fetus was confirmed as GHR deletion in exon 5-6, carrier. A non-affected baby was born.

## CONCLUSION

Here, we present a case demonstrating that using WGA as a template in addition to PCR targeting specific gene regions, exons 5 and 6 on the *GHR* gene, could identify LS carrier embryos. This provides evidence that WGA and PCR serve as an excellent tool to detect this specific monogenic disease in IVF embryos, thus allowing selection of candidate embryos for transfer successfully when a specific inherited genetic mutation/disease is suspected.

**Key words:** Growth hormone insensitivity; Growth hormone receptor mutations; Intragenic deletions; Molecular diagnosis; Embryo diagnosis; Laron syndrome; Case report

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Laron syndrome (LS) is a low prevalent, autosomal recessive hereditary disorder affecting the Jewish population; however, when LS is expected, genetic testing is required. This case study demonstrates that by using monoplex-polymerase chain reaction (PCR) during Pre-implantation Genetic Diagnosis, we were able to accurately identify mutations in the growth hormone receptor (GHR). Here, we show that, in Mexico, the cause of LS was the deletion of the exons 5 and 6 in the *GHR* gene; moreover, we were able to select an embryo, which produced an LS negative fetus. This study provides evidence that monoplex-PCR can serve as an excellent tool to detect diseases during *in vitro* fertilization.

**Citation:** Neumann A, Alcántara-Ortigoza MÁ, González-del Ángel A, Camargo-Díaz F, López-Bayghen E. Diagnosis of Laron syndrome using monoplex-polymerase chain reaction technology with a whole-genome amplification template: A case report. *World J Clin Cases* 2019; 7(23): 4029-4035

**URL:** <https://www.wjnet.com/2307-8960/full/v7/i23/4029.htm>

**DOI:** <https://dx.doi.org/10.12998/wjcc.v7.i23.4029>

## INTRODUCTION

The prevalence of Laron syndrome (LS), first described in 1966<sup>[1]</sup> as insensitivity to growth hormone (GH) due to mutations in the extracellular domain of the GH receptor (GHR)<sup>[2,3]</sup>, is not commonly diagnosed in Latin America. Moreover, in Mexico, there are less than 10 documented cases of LS<sup>[4-7]</sup>. LS is typically found among the Jewish community<sup>[8]</sup>, but with a very low prevalence. For Latin Americans, most cases are found in Ecuador, most likely of Jewish descendants, due to a mass migration during the 15<sup>th</sup> century<sup>[4]</sup>. Therefore, LS is typically not assessed in most Pre-implantation Genetic Testing (PGT), neither in Mexico nor in the rest of the world.

LS is an autosomal recessive disorder<sup>[9]</sup>, characterized by dwarfism, abnormal development of the reproductive organs (micropenis or enlarged breasts)<sup>[10-12]</sup>. Most LS patients have an increased risk for seizures<sup>[13]</sup> but a decreased risk for cancer<sup>[14-16]</sup>. LS subjects have elevated GH levels with usually low insulin-like growth factor 1<sup>[17]</sup>. To date, the diagnosis of LS is performed as a post-clinical presentation. Here, we present a case of a couple that underwent PGT to identify potential LS-free embryos to achieve a normal pregnancy.

## CASE PRESENTATION

### Chief complaints

A 31-year-old Jewish, Mexican woman [body mass index (BMI) = 21.76 kg/m<sup>2</sup>] and her husband, a 32-year-old Jewish, Mexican man (BMI = 24.5 kg/m<sup>2</sup>) decided to attend the INGENES Institute in Mexico City for selection of a healthy embryo for a second pregnancy, as her first pregnancy produced a child with LS.

### History of present illness

Both parents were presented as fully developed adults with healthy sexual development. Upon the diagnosis of LS, the borne-child mutation in the GHR descendant as deletion of exons 5 and 6 (del5-6) of GHR. Subsequent clinical and molecular analysis of the parents confirmed that they were carriers (heterozygotes) of the del5-6. We proposed an *in vitro* fertilization (IVF) protocol, complemented with pre-implantation genetic diagnosis (PGT) using monoplex polymerase chain reaction (PCR) targeting the del5-6 mutation present in GHR, as an intervention for healthy embryo selection.

### History of past illness

The only relevant history is five years before attending INGENES, the mother had one previous pregnancy, which resulted in a child with LS. Afterward, both patients underwent genetic testing, not at our facility, and were diagnosed as carriers for mutations in GHR that could develop LS.

### Personal and family history

The mother had no additional medical complications, nor was not taking any medications. For the father, no causes of male infertility were suspected; furthermore, he was healthy. Both parents are Jewish.

### Physical examination upon admission

**IVF and embryo isolation:** IVF, embryo biopsy and PGT were performed according to the standard protocols of the INGENES Institute as previously described (Cedillo 2016; Schaeffer 2017). The mother underwent two standard courses of controlled ovarian stimulation (Depot GnRH antagonist, Cetrotide 0.25 mg daily dose, Merck, Darmstadt, Germany). Stimulation was prolonged until the diameter of leading follicles was > 18 mm. Afterward, recombinant human chorionic gonadotropin (hCG, Choragon 1000 IU, Ferring Laboratories, Saint-Prex, Switzerland) was administered; then, after 36 h, the oocytes were retrieved with ultrasound guidance. All 14-18 mm follicles were aspirated, and 35 ova were collected (summed total for both stimulations). It was decided to proceed with fertilization and culture.

The ova were fertilized by intracytoplasmic sperm injection, and 25 embryos were produced. Only morphologically optimal embryos were considered for this study, using the criteria established by the Istanbul consensus Workshop on Embryo Assessment<sup>[18]</sup>. Eleven embryos presented as good quality (AB/BB) embryos by Embryo day 5 and were biopsied. Using micromanipulation, 10-15 trophoctoderm cells per embryo were isolated and placed into a 0.2 µL PCR tube; afterward, the embryos were frozen.

**Embryo transfer and pregnancy test:** For day 5 biopsied embryos, the resulting blastocysts were cryopreserved using the vitrification technique. The endometrial preparation was carried out with the transdermal application of 17-β-estradiol (Evorel 50; 150 µg/subcutaneous/every 48 h) and the luteal phase support was carried with Utrogestan (300 mg/day/vaginal). Clinical decisions about which and how many embryos to transfer were determined by the Physician and Specialist in Reproductive Medicine with the patient's approval. Embryo implantation was confirmed on day 14 by β-hCG serum levels >10 mUI/mL or the presence of a fetal heartbeat by ultrasound at 6.5 to 8 wk. All the patient's demographics, IVF cycle, PGT results, implantation rate, and IVF outcomes (pregnancies and miscarriages) were recorded by the Specialist.

### Laboratory examinations

**Whole genome amplification and next-generation sequencing:** Biopsies were taken from trophoctoderm from at-risk LS embryos. For each sample, the whole genome was amplified (WGA) using the SurePlex amplification system (Illumina San Diego, CA, United States) according to the manufacturer's instructions. WGA products were quantified using Qubit 3.0 Fluorometer (Life Technologies). The library preparation was carried out with the VeriSeq PGS Library Prep Kit (Illumina Inc.). DNA indexing was performed to simultaneously analyze samples from different embryos using the



Nextera XT 96-Index Kit (Illumina, Inc.). For library preparation, 5 µl (0.2 ng/µL) of each WGA product from each sample were tagged (tagged and fragmented) by the VeriSeq PGS transposome using the manufacturer's protocol and neutralized by adding 5 µL of neutralization buffer. The tagged DNA was amplified with Index 1 primers (N701 and N712) and Index 2 primers (S503 and S504) to become the next-generation sequencing (NGS) library via a limited cycle PCR program. Each sample's NGS library was purified to remove short fragments and primers. Finally, NGS libraries were pooled, denatured with HT1, and loaded to the VeriSeq PGS (Illumina Inc.) sequencing cartridge following the manufacturer's protocol. NGS library was sequenced with a MiSeq apparatus using the MiSeq Reporter Software. Chromosome composition was determined as indicated above.

**Determination of GHR mutations presence:** Successful WGA was verified by agarose electrophoresis, which revealed an optimal DNA concentration to carry-out the PCR amplification of a 186-bp specific fragment of the deletion breakpoint of exons 5 and 6 of the *GHR* gene (NM\_000163.4, 5p13-p12, MIM+600946) using the primers "5606" and "5662" and according to conditions previously published<sup>[19]</sup>. These primers would amplify a 186-bp fragment in both homozygous and heterozygous del5-6 genotypes, but not in normal wild-type samples. To distinguish the homozygous (affected) from heterozygous (carrier) del5-6 *GHR* genotype, a second end-point PCR assay was performed simultaneously with the primers "4947" and "5077" (19) to obtain a 269-bp fragment that evaluates the integrity of exon 5, which is present both in heterozygous del5-6 and wild-type *GHR* genotypes. These PCR assays were previously validated in genomic DNA samples derived from peripheral blood leukocytes from the unaffected obligate del5-6 heterozygous parents, as well as in their affected homozygous child with LS. All PCR assays were done in duplicate using 60 ng of WGA-derived DNA per reaction from at-risk LS and normal control, embryos ( $n = 3$ ), the two heterozygous parents and the homozygous LS-affected child (DNA samples were isolated by standard genomic DNA isolation from blood), and water as a control. Amplicons were resolved by agarose gel electrophoresis stained with ethidium bromide and visualized and photographed under ultraviolet light (Figure 1).

**Confirmation of implantation and fetus GHR mutational status:** Embryo implantation was confirmed on day 14 by  $\beta$ -hCG serum levels  $> 10$  mUI/mL or the presence of a fetal heartbeat by ultrasound at 6.5 to 8 wk. The genomic composition of the fetus was verified and confirmed by applying the same techniques (WGA obtained from amniotic cells and PCR) using amniocytes extracted after 21 wk of the ongoing pregnancy (Figure 2).

---

## FINAL DIAGNOSIS

Eleven embryos were collected from 2 rounds of IVF; 27.3% were the wild type for *GHR*, 45.5% were heterozygotes, and 18.2% homozygous mutants. One embryo yielded no results. Eight embryos were determined acceptable for transference. The patients agreed to have two embryos transferred.

---


## TREATMENT

Three 2-embryos transfers were performed (2 normal homozygous and 4 heterozygous carriers) were selected for transfer. The first 2 transfers were unsuccessful, whereas the final transfer, with 2 heterozygous embryos, resulted in a clinical pregnancy ( $\beta$ -hCG serum levels = 252.28 mUI/mL and the presence of one fetal heartbeat sac). The genomic composition of the fetus was verified, applying the same techniques but using DNA from amniocytes, extracted after 21 wk of the ongoing pregnancy. The fetus was confirmed as a heterozygous healthy carrier.

---

## OUTCOME AND FOLLOW-UP

At 36 wk, the mother delivered a healthy baby. No physical deformities were present, suggesting the absence of LS. Moreover, at age 11 mo, the child was clinically confirmed as normal by the family pediatrician.




**Figure 1** Electrophoresis of the monoplex polymerase chain reaction assay to identify the deletion of exons 5 and 6 (del5-6) of the growth hormone receptor gene for *in vitro* fertilization embryos. Lanes E1 to E4 show the whole genome amplification-DNA corresponding to the embryos being analyzed. Lanes L1 to L3 shown the controls previous known to have the deletions. L1 (paternal: heterozygous for del5-6), L2 (affected child: homozygous for del5-6), L3 (maternal: heterozygous for del5-6), masculine (positive control for a homozygous male normal), (-) water control, MWM molecular weight marker (right lane). E1 and E3 show a del5-6, only E1 shows a deletion of ex5, meaning that E1 is homozygous affected, E3 is a heterozygous carrier, and E2 and E4 are wild-types for the deletion causing Laron syndrome. GHR: Growth hormone receptor.

## DISCUSSION

In the review by Zvi Laron in 2015, the author indicates that the use of PGT can aid LS patients to have healthy children; however, a search of the literature yielded no studies supporting this claim<sup>[8]</sup>. Here, we present a case study where a couple underwent IVF to select embryos that were wild-type or heterozygous carriers of the GHR mutations previously characterized in the parents. The procedure was successful, as a fetus amnion-analysis result excludes in the fetus in gestation the clinical and molecular diagnosis of LS attributable to a homozygous genotype for the pathogenic deletion that eliminates exons 5 and 6 ("del5-6") of the *GHR* gene previously characterized in the parents. Likewise, the absence of the "del5-6" fragment excludes the healthy carrier/heterozygous character in the fetus for LS due to the pathogenic deletion that eliminates exons 5 and 6 of the *GHR* gene. Eventually, the child was born and was physiologically normal.

One key concern for the procedure was the DNA source. With most LS patients, sample DNA comes from blood or buccal samples. With embryos, the DNA is more limited as for actual day 5-trophectoderm biopsies from blastocyst produce 10 to 15 cells for extraction of genomic DNA. To improve the signal, WGA was performed. With our method and using control samples (the parents, their affected child, and normal embryos), we can show the specificity of the monoplex PCR to determine the del5-6 of GHR. Moreover, when we applied the method to the embryo cohort, we determined that a minority of embryos would be unsuitable for implantation. When the selected embryos were implanted, we were able to confirm the genotype of the fetus, demonstrating the applicability of the method.

There are over 70 documented mutations associated with the development of LS<sup>[20]</sup>. For Latin Americans, the E180 polymorphism is the most common due to a mass migration to Ecuador<sup>[21]</sup>; nevertheless, the E180 polymorphism has been found in Brazil, Argentina, and Mexican-descendants in the United States<sup>[4]</sup>. Recently, in Monterrey, Mexico, three patients were identified with LS, and the key mutations that were identified as possible causes were not of GHR<sup>[5-7]</sup>. Here, we demonstrate that the LS in the parents was associated with the del5-6 of GHR. This is the first report to



**Figure 2** Electrophoresis of the monoplex polymerase chain reaction assay to determine the growth hormone receptor mutational status in the fetus of the pregnant mother. Amniocytes were extracted and were analyzed in triplicate by generating genomic DNA using the same procedure for embryos. 56009-LA-1 to -3 are the 3 independent analyses of the amniocytes. L1 (paternal: heterozygous for del5-6), L2 (affected child: homozygous for del5-6), L3 (maternal: heterozygous for del5-6), masculine (positive control for a homozygous male normal), (-) is the water control and the molecular weight marker. Results showed the presence of at least one copy of exon 5 of the growth hormone receptor gene; therefore, it can be concluded that the fetus will not present with Laron Syndrome but be a carrier (heterozygote) of Laron syndrome. GHR: Growth hormone receptor.

demonstrate the presence of this mutation in Mexico.

Interestingly, the connection with this family and other locations where the mutation is present is difficult to discern. Other than the family being Jewish, there is not another connection. This suggests that, for the Jewish population, members may want to undergo genetic analysis of common diseases.

## CONCLUSION

In conclusion, to detect the del5-6 of GHR using WGA embryonic DNA and monoplex-PCR can identify LS at-risk embryos during PGT. Moreover, we provide evidence that WGA is useful and can serve as a template to diagnose other monogenic diseases pre-implantation in patients undergoing fertility treatments.

## ACKNOWLEDGEMENTS

We would like to express our gratitude to the participants of the study, to Tania Rojas for their technical assistance in PGT, to the members of the INGENES-IVF Laboratory, and to Dr. Leonardo M. Porchia for his contributions in preparing the manuscript.

## REFERENCES

1. **Laron Z**, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentration of growth hormone--a new inborn error of metabolism? *Isr J Med Sci* 1966; **2**: 152-155 [PMID: [5916640](#) DOI: [10.1016/j.jtbi.2005.02.019](#)]
2. **Godowski PJ**, Leung DW, Meacham LR, Galgani JP, Hellmiss R, Keret R, Rotwein PS, Parks JS, Laron Z, Wood WI. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism. *Proc Natl Acad Sci U S A* 1989; **86**: 8083-8087 [PMID: [2813379](#) DOI: [10.1073/pnas.86.20.8083](#)]
3. **Amselem S**, Duquesnoy P, Attree O, Novelli G, Bousnina S, Postel-Vinay MC, Goossens M. Laron dwarfism and mutations of the growth hormone-receptor gene. *N Engl J Med* 1989; **321**: 989-995 [PMID: [2779634](#) DOI: [10.1056/NEJM198910123211501](#)]
4. **Gonçalves FT**, Fridman C, Pinto EM, Guevara-Aguirre J, Shevah O, Rosembloom AL, Hwa V, Cassorla F, Rosenfeld RG, Lins TS, Damiani D, Arnhold IJ, Laron Z, Jorge AA. The E180splice mutation in the GHR gene causing Laron syndrome: witness of a Sephardic Jewish exodus from the Iberian Peninsula to the New World? *Am J Med Genet A* 2014; **164A**: 1204-1208 [PMID: [24664892](#) DOI: [10.1002/ajmg.a.36444](#)]
5. **Castilla-Cortazar I**, Femat-Roldán G, Rodríguez-Rivera J, Aguirre GA, García-Magariño M, Martín-Estal I, Espinosa L, Díaz-Olachea C. Mexican case report of a never-treated Laron syndrome patient evolving to metabolic syndrome, type 2 diabetes, and stroke. *Clin Case Rep* 2017; **5**: 1852-1855 [PMID: [29152285](#) DOI: [10.1002/ccr3.1193](#)]
6. **Castilla-Cortazar I**, De Ita JR, Aguirre GA, García-Magariño M, Martín-Estal I, Lara-Díaz VJ, Elizondo MI. Growth hormone insensitivity: Mexican case report. *Endocrinol Diabetes Metab Case Rep* 2017; 2017 [PMID: [29147569](#) DOI: [10.1530/EDM-17-0126](#)]
7. **Castilla-Cortazar I**, De Ita JR, Aguirre GA, Castorena-Torres F, Ortiz-Urbina J, García-Magariño M, de

- la Garza RG, Diaz Olachea C, Elizondo Leal MI. Fanconi Anemia and Laron Syndrome. *Am J Med Sci* 2017; **353**: 425-432 [PMID: [28502327](#) DOI: [10.1016/j.amjms.2017.02.001](#)]
- 8 **Laron Z.** Lessons from 50 years of study of laron syndrome. *Endocr Pract* 2015; **21**: 1395-1402 [PMID: [26401581](#) DOI: [10.4158/EP15939.RA](#)]
- 9 **Hamosh A.** 262500 Laron Syndrome in Online Mendelian Inheritance in Man. Available from: <https://www.omim.org/entry/262500?search=Laron%20syndrome&highlight=%28syndrome%7Csyndromic%29%20laron>
- 10 **Laron Z, Ginsberg S, Lilos P, Arbiv M, Vaisman N.** Body composition in untreated adult patients with Laron syndrome (primary GH insensitivity). *Clin Endocrinol (Oxf)* 2006; **65**: 114-117 [PMID: [16817829](#) DOI: [10.1111/j.1365-2265.2006.02558.x](#)]
- 11 **Phanse-Gupte SR, Khadilkar VV, Khadilkar AV.** Clinical features and endocrine profile of Laron syndrome in Indian children. *Indian J Endocrinol Metab* 2014; **18**: 863-867 [PMID: [25364685](#) DOI: [10.4103/2230-8210.140236](#)]
- 12 **Laron Z, Mimouni F, Pertzlan A.** Effect of human growth hormone therapy on penile and testicular size in boys with isolated growth hormone deficiency: first year of treatment. *Isr J Med Sci* 1983; **19**: 338-344 [PMID: [6406387](#)]
- 13 **Bissonnette B, Luginbuehl I, Marciniak B, Dalens BJ.** Syndromes: Rapid recognition and perioperative implications. 1st ed. McGraw-Hill New York, NY, 2006.
- 14 **Shevah O, Laron Z.** Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report. *Growth Horm IGF Res* 2007; **17**: 54-57 [PMID: [17166755](#) DOI: [10.1016/j.ghir.2006.10.007](#)]
- 15 **Steerman R, Shevah O, Laron Z.** Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies. *Eur J Endocrinol* 2011; **164**: 485-489 [PMID: [21292919](#) DOI: [10.1530/EJE-10-0859](#)]
- 16 **Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, Hwang D, Martin-Montalvo A, Saavedra J, Ingles S, de Cabo R, Cohen P, Longo VD.** Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. *Sci Transl Med* 2011; **3**: 70ra13 [PMID: [21325617](#) DOI: [10.1126/scitranslmed.3001845](#)]
- 17 **Koren D, Palladino A.** Hypoglycemia. Genetic Diagnosis of Endocrine Disorders. 2nd ed. Elsevier. 2016; 31-75 [DOI: [10.1016/B978-0-12-800892-8.00003-8](#)]
- 18 **Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology.** The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. *Hum Reprod* 2011; **26**: 1270-1283 [PMID: [21502182](#) DOI: [10.1093/humrep/der037](#)]
- 19 **Gastier JM, Berg MA, Vesterhus P, Reiter EO, Francke U.** Diverse deletions in the growth hormone receptor gene cause growth hormone insensitivity syndrome. *Hum Mutat* 2000; **16**: 323-333 [PMID: [11013443](#) DOI: [10.1002/1098-1004\(200010\)16:4<323::AID-HUMU5>3.0.CO;2-D](#)]
- 20 **Janecka A, Kolodziej-Rzepa M, Biesaga B.** Clinical and Molecular Features of Laron Syndrome, A Genetic Disorder Protecting from Cancer. *In Vivo* 2016; **30**: 375-381 [PMID: [27381597](#)]
- 21 **Berg MA, Guevara-Aguirre J, Rosenbloom AL, Rosenfeld RG, Francke U.** Mutation creating a new splice site in the growth hormone receptor genes of 37 Ecuadorean patients with Laron syndrome. *Hum Mutat* 1992; **1**: 24-32 [PMID: [1284474](#) DOI: [10.1002/humu.1380010105](#)]



Published By Baishideng Publishing Group Inc  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
Telephone: +1-925-2238242  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>

